Conducting Clinical Trials in Turkey
|
|
- Austin Randall
- 8 years ago
- Views:
Transcription
1 Conducting Clinical Trials in Turkey A Resource for Sponsors Prepared by: Ömer Sadun Okyaltırık Pharm-Olam Turkey Country & Clinical Operations Manager Yamin Mo Khan Pharm-Olam International, Executive Vice President, Clinical Development
2 Table of Contents Forward... 2 Country Overview... 3 Demographics Incidence of Disease Leading Causes of Death... 6 Disease Profile... 7 Healthcare Agenda... 8 Health Infrastructure Types of Hospitals Healthcare Professionals Regulatory Process Why Turkey? Opportunities and Challenges Conclusion About the Authors Forward This paper is intended to serve as a resource for research-oriented pharmaceutical companies planning to sponsor international clinical research projects in Turkey. It presents a broad overview of the country s clinical research environment encompassing: population demographics; disease burden; access to medicine; and the country s healthcare agenda, infrastructure, legislation, and experience with clinical trials. R&D-oriented companies developing new medicines must, of course, generate reliable data through their trial process. Doing so requires access to a sufficiently large patient population and experienced investigators working in compliance with internationally accepted guidelines, local regulations, ethical principles, and common considerations. For this reason, we believe that clinical research professionals searching new regions for suitable research sites should consider Turkey; in our view, it is a favorable environment for conducting clinical research studies. 2 I Clinical Trials in Turkey: A Resource for Sponsors
3 Country Overview Turkey, officially known as the Republic of Turkey, covers a large area lying between Europe and Asia with a population of over 76 million. The capital of Turkey is Ankara, and Istanbul is its largest city with over 10 million people. Other major metropolitan areas each with over one million residents include Izmir, Bursa, and Adana. Healthcare services have emerged as one of the country s most important business areas in the 21st century, due to the aging population and worldwide changes in socioeconomic structures. Inevitably, the risk of chronic diseases increases with the extended average life expectancy. Thus, it is expected that innovative new treatments will gain increasing importance over time as they help to prevent disease and reduce treatment costs. 1 Turkey is located at the center of an emerging region where the number of industry-sponsored clinical trials is steadily increasing. Many multinational pharmaceutical companies which do not yet have offices in Turkey are looking for ways to conduct their clinical research projects in Turkey. They recognize the systematic and organized work Turkey has been doing to enhance TURKEY the country s healthcare sector. The first clinical research activities in the country date back to the 1990 s, and the first regulation in pharmaceutical research was published in Turkey can contribute significant patient data to future clinical trials as it offers: A large and eager patient population with high enrollment rates A growing middle class Competitive trial budgets A high number of investigators trained in Good Clinical Practices (GCPs) and having multinational/multi-center experience A modern and developed technical infrastructure Ethics Committees with standard principles Newly updated, comprehensive regulations 1 Clinical Trials in Turkey: A Resource for Sponsors I 3
4 Demographics The portion of the patient population requiring new medications in Turkey is increasing every day along with the population s longevity. The median age is 29.2 years, and the average life span, which has increased by 24% over the last 30 years, is now 74 years. Roughly three-quarters of the Turkish people live in urban centers, and nearly all are literate. 4 I Clinical Trials in Turkey: A Resource for Sponsors
5 Table 1: Turkish Demographics, 2013 Population 80,694,485 Age Structure 0-14 years 25.9 (10,682,900 male, 10,201,965 female) years 17% (6,979,955 male, 6,703,689 female) years 42.7% (17,375,544 male, 17,097,927 female) years 7.9% (3,189,731 male, 3,169,450 female) 65 years and over 6.6% (2,422,983 male, 2,870,341 female) Median Age Total 29.2 years Male 28.8 years Female 29.2 years Population Growth Rate 1.16% Birth Rate births (per.000 population) Death Rate 6.11 deaths (per.000 population) Urbanization Urban population 71.5% of total population Rate of urbanization 2.4% annual rate of change Major Cities - Population Istanbul million Ankara million Izmir million Bursa million Adana million Sex Ratio At birth 1.05 male(s) / female 0-14 years 1.05 male(s) / female years 1.04 male(s) / female years 1.02 male(s) / female years 1.01 male(s) / female 65 years and over 0.84 male(s) / female Total population 1.02 male(s) / female Life Expectancy at Birth Total population years Male years Female years Ethnic Groups Turkish 70-75% Kurdish 18% Other Minorities 7-12% Literacy Definition Age 15 and over can read and write Total population 94.1% Male 97.9% Female 90.3% Source: Turkish Agency of Statistics (TurkStat), Clinical Trials in Turkey: A Resource for Sponsors I 5
6 Incidence of Disease Leading Causes of Death Diseases of the circulatory system are responsible for nearly 40 percent of deaths in Turkey. 2 Indeed, Turkish women have the highest mortality from coronary heart disease in Europe. 3 Causes of Death Diseases of the Circulatory System Malignant Neoplasms Disease of the Respiratory System Endocrine, Nutritional, and Metabolic Diseases External Causes in Injury and Poisoning Other (Infectious and Parasitic Diseases, Mental and Behavioral Disorders, Diseases of the Musculoskeletal System and Connective Tissue, etc.) TOTAL (Percentage) I Clinical Trials in Turkey: A Resource for Sponsors
7 Disease Profile IMS Health also reports, Turkey s health disease burden and health indicators vary significantly from major urban centers, where they are approaching European standards, to outlying rural areas, particularly in Eastern Turkey, where tuberculosis (TB) and similar infections still occur. 4 According to a Report by the UCL School of Pharmacy 5 : The disease profile in Turkey is shifting away from infectious diseases toward non-communicable diseases, which account for 70 percent of all mortality in the country. 6 The incidence of Type 2 Diabetes has doubled in a little more than a decade, above the rate of increase in the U.S. More of the population is becoming obese (particularly less advantaged women) and about one quarter of adults in the country have clinically significant raised cholesterol levels. At least a third of the population have clinically significant hypertension, nearly half of whom are unaware of their condition. Nearly 150,000 new cancer patients are diagnosed each year in Turkey (with lung cancer being the most frequent tumor type), as indicated by the World Health Organization. 7 2 Causes of Death Statistics, 2010, 2011, and 2012, Turkish Statistical Institute, No: 15847, April 16, Transforming Health in Turkey: 21st Century Opportunities, UCL School of Pharmacy, September, IMS Health, Country Report: Turkey, Pharmaceutical Market Europe, May Transforming Health in Turkey: 21st Century Opportunities, UCL School of Pharmacy, September, Transforming Health in Turkey: 21st Century Opportunities, UCL School of Pharmacy, September, World Health Organization International Agency for Research on Cancer, Globocan 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in Clinical Trials in Turkey: A Resource for Sponsors I 7
8 Healthcare Agenda The Turkish Government aims to make Turkey one of the world s top ten economies in health services by 2023 by 1) increasing R&D expenditures to three percent of GDP and 2) by increasing exports to USD $500 billion. Moreover, according to a Strategy Report from the Turkish Ministry of Science, Industry, and Technology (AIFD), Turkey is slated to become the Eurasian production base for medium- and high-level technology products. Taking into account Turkey s current macroeconomic conditions, political stability, and increasing economic efficiency, AIFD considers these R&D targets to be realistic. 8 Turkey s Healthcare Transformation Program, which was implemented in 2004, marked a major development in public access to health services and treatments. Physician consultation per capita increased five times from 1.7% in 1994 to 7.7% in And, innovative treatments are playing a significant role in increasing life expectancy. Based on a study of conducted by Professor Lichtenberg of Columbia University and the National Bureau of Economic Research, innovative drugs accounted for 75% of the increase in life expectancy in the 30 countries surveyed, including Turkey I Clinical Trials in Turkey: A Resource for Sponsors
9 Health Infrastructure Types of Hospitals The number of hospitals in the country has climbed steadily since As of 2010, there are more than 1,400 hospitals in Turkey across three basic types of facilities, as seen in Figure 1: University Hospitals (62) Ministry of Health (843) Private and Foundation Hospitals (489) Figure 1: Number of Hospitals in Turkey Number of Institutions % BYBO MOH Private University Health Expenditures Source: Report on Turkey s Health Sector, Deloitte, June Clinical Trials in Turkey: A Resource for Sponsors I 9
10 Together, these institutions have 2.5 beds per 1,000 population and maintain a total bed occupancy rate of around 64%. Most of the hospital admissions are to hospitals affiliated to the Ministry of Health (MOH) as seen in Figures 2 and 3. Figure 2: Number of Inpatients by Year and Sector Number of Inpatients by Year and Sectors (.000) Number of Patients Hospitalized (.000) Source: Health Statistics Yearbook 2012, Turkish Ministry of Health General Directorate for Health Services, p I Clinical Trials in Turkey: A Resource for Sponsors
11 Figure 3: Distribution of Hospitalized Patients by Hospital Type Distribution of Hospitalized Patients Source: Health Statistics Yearbook 2012, Turkish Ministry of Health General Directorate for Health Services, p. 98 Clinical Trials in Turkey: A Resource for Sponsors I 11
12 Distribution of Hospitals The number of private hospitals is growing rapidly, and they hold much potential as future trial sites. The distribution of private hospitals is heavily weighted toward three leading cities: Istanbul, Ankara, and Izmir, which together have 48% of the country s private hospitals and 56% of the total available beds. See Figure 4. Figure 4: Distribution of Private Hospitals Across Metropolitan Areas in Turkey 2% Istanbul 38% 3% Izmir 5% 2% 2% Ankara 6% 3% 3% 2% 2% 2% Source: Turkish Yearbook of Statistics, 2010 (2008 data), Turkish Agency of Statistics As a matter of fact, providing medical care to social security patients is becoming more costly each day, and the costs are reflected to the patients at the end of the day. This brings additional burdens to the patients. Therefore participation in clinical trials is becoming more attractive in Turkey, as a mutual benefit both for the hospitals and for the patients, because as all trial related expenses can be reimbursed to the hospitals by the sponsors, while patients are being provided with full medical care at no cost at all. Likewise the sponsors have the chance this way to obtain adequate data for their clinical trials. This has also some positive impact on triggering clinical trials in private settings. The legislation allowing clinical research to be conducted in private hospitals is rather new 10, thus few have conducted studies to date, and most of the clinical research projects have been conducted so far in university hospitals and those affiliated with the MOH. 10 Turkish Official Gazette, 13 April 2013, issue no Amended on 25 June 2014, issue no: I Clinical Trials in Turkey: A Resource for Sponsors
13 Healthcare Professionals Currently there are a total of 130,000 physicians in Turkey, according to research conducted by the Turkish Health Union. 11 Of these, 75,000 doctors are working in the MOH setting. And of those, 33,812 are specialists, 32,607 are general practitioners and 8,500 are assistants. Istanbul, Ankara, and Izmir are the leading cities in terms of the number of doctors: 30% of the total number of doctors is found in these three large cities. Figure 5: Distribution of Healthcare Professionals by Institution Type As seen in Figure 5, slightly less than two thirds (59%) of physicians in Turkey work in state hospitals affiliated with the Ministry of Health, while 20% work in the private settings. 12 Distribution of Healthcare Professionals According to the Institutions % %.7% 3.5% 3.7% 8.4% 19.5% 22.8% 15.0% 20.6% 7.5% 13.8% 60.6% 88.7% 90.4% 58.7% 5.7% 69.7% 67.5% 33.0% 7.0% 0.8% Physician Dentist Pharmacist Medical Officer Nurse Midwife Ministry of Health University Private Other 1.1% Annual of Health Statistics, 2010 Clinical Trials in Turkey: A Resource for Sponsors I 13
14 Clinical Trials The first regulations for conducting clinical trials in Turkey were introduced in 1993, and over the past 20 years, the country has come a long way in supporting clinical research. Today Turkey is a serious candidate to become a clinical research hub in the Eastern Europe - Middle East - North Africa triangle. Organizations such as the Foundation of Research-Based Pharmaceutical Companies (AIFD), the Foundation for Clinical Research, and the Foundation of Contract Research Organizations all work to enhance the clinical trial environment in Turkey. The AIFD s vision for Turkey is that it will become an R&D and manufacturing center on a global scale, a goal reflected in its slogan, 2023 Will Come as the Remedy. (See Figure 6). Figure 6: Projection of Pharmaceutical R&D in Turkey, through 2023 Pharmaceutical Research and Development in Turkey Vision 2023 Projection Million $ Amount of Investment , ,600 1,650 1, Number of Clinical Trials Investment in Clinical Total Pharmaceutical R&D Number of Clinical Research (million $) Spendings (million $) Research Projects Source: Projection of the Association of Research-Based Pharmaceutical Companies 14 I Clinical Trials in Turkey: A Resource for Sponsors
15 Number of Trials As of September 2014, approximately one percent (1,616) of the world s 174,221 clinical research projects has been conducted in Turkey. 13 According to the World Economic Forum s Global Competition Index ( ), while the Turkish pharmaceutical sector is ranked 16th in terms of market value, it is 36th in terms of the clinical research conducted and the volume of pharmaceutical exports. 14 As seen in Figure 7, the number of clinical trials in Turkey has been climbing steadily for the past several years. Between 2012 and 2013, the number increased 12%. Figure 7: Number of Clinical Trials in Turkey, 2006 Feb Number of Clinical Trials in Turkey Q1 06 Q3 06 Q3 07 Q3 08 Q3 09 Q3 10 Q3 11 Q3 12 Feb 13 Total Industry Other (University, EORTC etc.) NIH Source: AIFD data derived from clinicaltrials.gov Clinical Trials in Turkey: A Resource for Sponsors I 15
16 Trial Types and Locations Sponsors are conducting clinical trials of all phases in Turkey, as shown in Figure 8, although most are in Phase III. Figure 8: Clinical Trials by Phase, 2014 Number of Clinical Phase Studies Source: Clinicaltrials.gov; as of August 20, I Clinical Trials in Turkey: A Resource for Sponsors
17 Figure 9 illustrates that the vast majority of trials in the country are interventional while nearly 20% are observational. Figure 9: Types of Clinical Trials in Turkey Source: Clinicaltrials.gov; as of August 20, 2014 Phase I clinical trials and bioavailability bioequivalence studies are conducted within the Ministry of Health hospitals and universities. These facilities must be approved by the regulatory authority, offer emergency treatment, and satisfy all applicable standards. These studies are conducted by teams with training and experience in good clinical practices and by pharmacologist physicians who have completed specialty education or a doctorate degree. Currently in Turkey, there are only two approved and certified Phase I centers; ARGEFAR - Ege University and Ege University Hospital of Pediatrics Department of Hematology. This number is likely to increase in the near future, as cities in Turkey are developing as centers of advanced technology. Clinical Trials in Turkey: A Resource for Sponsors I 17
18 Regulatory Process Recent measures to improve the applicable regulations have strengthened interest in conducting clinical research in Turkey. The country has taken major steps towards harmonizing its research legislation with that of the European Union, and Turkish regulations are now totally in line with EC Directives (EC 2001/20 and EC 2005/28). Regulations on clinical trials are reviewed periodically and amended as required to comply with the most stringent international standards and ethical principles. The MOH has created a clinical research unit which serves as the Country Authority to assess and grant approvals for clinical trials. Submissions must be made to both the MOH and a local Ethics Committee (EC). ECs have also been established in all localities, with 99 being approved at the time of writing. Members are required to have had education in Good Clinical Practices (GCPs). Applications can be submitted to any approved EC, and the decision of one Ethics Committee shall be sufficient for multi-center clinical trials. (See Figure 10.) Figure 10: Site Evaluations Site Selections Collection of Submission Documents Submissions Coordinating Site Ethics Committee MOH Ethics Committee Electronic Submission Physical Submission 60 days from Submission 90 days from Submission Import License Application (2-3 weeks) 18 I Clinical Trials in Turkey: A Resource for Sponsors
19 Sponsors must apply to the MOH for the license to import the Investigational Product(s). Importing IP requires a pro forma invoice for the shipment, an Import Customs Declaration, and relevant international shipping documents. Under normal circumstances, approval is granted in about 15 days. The entire process is expected to take between 45 to 60 days, as indicated in the regulation published by the Ministry of Health. However, from time to time this period is likely to extend to around 90 days depending on the workload of the Ethics Committees. Generally the best case is to be able to initiate a project within 75 days, including receipt of the import license. In the worst case, full approval might take 90 to 120 days, depending on the workload of the assessment committees. Trial Sites Clinical trials may only be conducted at suitable sites having the appropriate staff, equipment, laboratory capabilities, and emergency care to ensure the safety of research volunteers. These include: Centers for health practice and R&D established within universities Military training and research hospitals Ministry training and research hospitals Private hospitals Updated Legislation The current Turkish regulation on clinical research (originally published on 13 April 2013 in #28617) was updated 25 June 2014 in #29041, making it even easier to start and conduct clinical trials in the country, through the following changes: Both the MOH submission and the EC submission can now be completed in parallel, saving considerable time for sponsors and CROs. Submissions to the Ministry of Health can be made electronically another timesaver for sponsors. Applications can be sent to any EC, whether or not it is to be involved in the particular research project. Clinical trials can be performed in private settings Clinical trial documents must be archived for 5 years (instead of 14) The update also mandates that all clinical trials must be published in a public Internet database managed by the MOH. However, the Clinical Research Association in Turkey has also created a similar site, in cooperation with the clinicaltrials. gov database. Clinical Trials in Turkey: A Resource for Sponsors I 19
20 Why Turkey? Opportunities Turkey is one of the most convenient and productive countries in which to invest for clinical research and is aiming to become one of the foremost countries in the clinical research area. 15 The economy is one of the fastest growing in the world, and the volume of pharmaceuticals imported and exported has increased two fold in the last five years. Turkey represents a fertile market in the clinical research business, boasting: A developing clinical research profile supported by new regulations in clinical research that are in accordance with international standards and European Directives. A large and diverse patient population of almost 80 million, a large percentage of which are treatment naïve. Consequently, the people of Turkey are highly motivated to participate in studies, and ready access to them makes for rapid enrollment. A high number of sites with the capacity to conduct clinical research 62 university hospitals, 489 private hospitals and 843 government hospitals 16 Highly motivated research teams trained in GCP and capable of producing high quality, reliable data Comparatively low costs, relative to EU countries and the U.S. Challenges Although most of the physicians in Turkey work in hospitals affiliated with the MOH, conducting clinical research in such settings requires approval from the Association of Public Hospitals. Because the Association is also involved in Clinical Trial Agreements, this may sometimes delay study start up. Fortunately, the Turkish Ministry of Health is working to create common standards in such hospitals, where current fees for physical examinations, tests, and procedures vary from one facility to another. Other restrictions that may impede site and patient enrollment include: No payments can be made to assistant personnel No advertising can be done to recruit patients for clinical trials No payments can be made to patients in return for their participation in clinical trials TurkStat, Turkish Agency of Statistics Hospital Number Report, June I Clinical Trials in Turkey: A Resource for Sponsors
21 Another possible limiting factor is that investigators cannot be paid directly for their trial involvement; payments must be made to the circulating capital department of the relevant institutions. Ultimately, investigators only receive an average of 60 percent of the investigator fees that sponsors pay. There are still a number of inexperienced Ethics Committees in Turkey, so sponsors must take care to select ones that are properly prepared. This is easier now that applications can be sent to any Ethics Committee (rather than only the ones involved in particular project). Conclusion When considering clinical trial locations, sponsors seek countries with a well-established structure, a solid understanding of and adherence to global clinical trial management practices, and sufficient numbers of the targeted patients. They, of course, want to ensure that their research project delivers high-quality data in a timely manner. Turkey meets all of these basic requirements as well as offers an expedient regulatory process, a competitive cost structure, and a government committed to advances in public health and economic progress. The challenges to operating trials in Turkey are minor when weighed against the advantages and can easily be surmounted with the help of a partner familiar with the local practices and restrictions. Sponsor companies would do well to fully explore what Turkey has to offer their research programs. About the Authors Sadun Okyaltırık has developed knowledge and experience in the pharmaceuticals industry since beginning his career in He has focused on clinical research since Having started at Roche Turkey as a sales representative, Okyaltırık has been assigned to several positions such as Product Manager, Clinical Research Associate (CRA), and Sr. CRA positions in companies such as Pfizer, Aventis / Sanofi-Aventis, PPD, and finally Pharm-Olam. Currently he is conducting the Country Manager & Clinical Operations Manager duties in Pharm-Olam Turkey. Yamin Mo Khan is the Executive Vice President of Global Clinical Development at Pharm-Olam International, based in the UK. He has a PhD in Biochemistry and started in the industry in Prior to Pharm-Olam, Mo worked at a global CRO and a small biotech company. He has been with the Pharm-Olam for the last 14 years, during which time the company has grown from a small niche provider to a mid-sized global full service CRO with over 500 personnel. At Pharm-Olam, Mo has worked in Clinical Operations, Project Management, and Business Development. His major responsibility has been to ensure global project delivery and to build the Project Management group. In addition, he works with both new and current clients to build long-term relationships and assist in Business Development activities. Clinical Trials in Turkey: A Resource for Sponsors I 21
22 About Pharm-Olam International Pharm-Olam International is a global contract research company with a presence in over 40 countries, offering a wide range of comprehensive clinical research services to the pharmaceutical, biotechnology, and medical device industries. For more information on planning successful trials within Turkey, contact info@pharm-olam.com. Pharm-Olam International 450 North Sam Houston Parkway E., Suite 250 Houston, TX 77060, USA T: F: Pharm-Olam International (UK) The Brackens, London Road Ascot, Berkshire, SL5 8BJ, UK T: +44 (0) F: +44 (0)
NURSING IN EGYPT. Age. Female. Male EGYPT DEMOGRAPHICS PROFILE AGENDA. Net migration rate: -0.21 migrant(s)/1,000 population (2009 est.
AGENDA Egyptian Society Demographics Major Problems in Egypt NURSING IN EGYPT Egyptian System facilities Human resources for health Prof. Dr. Effat El-Karmalawy 2010 Egyptian Education System Education
More informationHEALTHCARE AND HEALTHCARE EQUIPMENTS
HEALTHCARE AND HEALTHCARE EQUIPMENTS With the coming into force of the much-sought Social Security and General Health Insurance Law as of 2007, private hospitals are under construction all over the country
More informationTürkiye İlaç ve Tıbbi Cihaz Kurumu
w w w. t i t c k. g o v. t r TURKISH MEDICINES AND MEDICAL DEVICES AGENCY Gulsen ONER, Pharm. M.Sc. Melda KECIK, Pharm. M.Sc. WHO Technical Briefing Seminar, November 2014 OUTLINE I. About Turkey II. About
More informationUsing population health data analytics to optimize medical device investment decisions
Research and Studies Using population health data analytics to optimize medical device investment decisions Mazen Hassanain, MD PhD WHO Second Global Forum on Medical Devices, Geneva, Nov. 23, 2013 Saudi
More informationAustralia Life Sciences Market
Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring
More informationPart 4 Burden of disease: DALYs
Part Burden of disease:. Broad cause composition 0 5. The age distribution of burden of disease 6. Leading causes of burden of disease 7. The disease and injury burden for women 6 8. The growing burden
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationHospitals and Health Systems:
Hospitals and Health Systems: An Inside Look at Employee Health Plan Strategies To Control Costs and Provide Access to Healthcare August 2010 Highlights Because of their dual role as benefit plan sponsor
More informationHEALTH TRANSITION AND ECONOMIC GROWTH IN SRI LANKA LESSONS OF THE PAST AND EMERGING ISSUES
HEALTH TRANSITION AND ECONOMIC GROWTH IN SRI LANKA LESSONS OF THE PAST AND EMERGING ISSUES Dr. Godfrey Gunatilleke, Sri Lanka How the Presentation is Organized An Overview of the Health Transition in Sri
More informationAgainst the Growing Burden of Disease. Kimberly Elmslie Director General, Centre for Chronic Disease Prevention
Kimberly Elmslie Director General, Centre for Chronic Disease Prevention Chronic diseases are an increasing global challenge Most significant cause of death (63%) worldwide 1 Chronic diseases cause premature
More informationUGANDA HEALTH CARE SYSTEM
UGANDA HEALTH CARE SYSTEM Community and Home based Rehabilitation Course Julius Kamwesiga KI May 2011 Objectives 1. Define a Health System 2. Describe how Ugandan Health care System is organized 3. Outline
More informationShutterstock TACstock
Shutterstock TACstock 10 Introduction Since 2000, the IDF Diabetes Atlas has detailed the extent of diabetes and this seventh edition shows how it is impacting every country, every age group and every
More informationChina s rising needs and opportunities. George Liu La Trobe University c.liu@latrobe.edu.au
China s rising needs and opportunities George Liu La Trobe University c.liu@latrobe.edu.au Healthcare market in China Consumer demands Service capacity Governmental control Healthcare demands Ageing population
More informationTHE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA
THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry
More informationNCDs POLICY BRIEF - INDIA
Age group Age group NCDs POLICY BRIEF - INDIA February 2011 The World Bank, South Asia Human Development, Health Nutrition, and Population NON-COMMUNICABLE DISEASES (NCDS) 1 INDIA S NEXT MAJOR HEALTH CHALLENGE
More informationThe Public Health Crisis in Kenya: and Economic Challenges
The Public Health Crisis in Kenya: An Inside Perspective on the Medical and Economic Challenges Mark Weisburst, MD, MBA, FACC, FACP Stanford Medical School Hartford Hospital University of Hartford Business
More informationClinical Trials in Latin America. A Region of Diversity, A World of Opportunity
Clinical Trials in Latin America A Region of Diversity, A World of Opportunity Latin America: A Region of Diversity, a World of Opportunity for Clinical Trial Sponsors Latin America is hardly the latest
More informationHealth and Health Care in India Policy implications for Europe
Health and Health Care in India Policy implications for Europe David Taylor Professor of Pharmaceutical and Public Health Policy University College London School of Pharmacy Dr Jennifer Gill Research Fellow
More informationA Journey to Improve Canada s Healthcare System
A Journey to Improve Canada s Healthcare System The Quest Can a public/private hospital system coexist and thrive and improve Canada s system? The Journey Visited Australia and New Zealand to find out
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationTackling Chronic Disease
Tackling Chronic Disease A Policy Framework for the Management of Chronic Diseases Hawkins House Dublin 2 Teach Haicin Baile Átha Cliath 2 Telephone (01) 6354000 www.dohc.ie ISBN: 978-1-40642135-4 Tackling
More informationHealth, history and hard choices: Funding dilemmas in a fast-changing world
Health, history and hard choices: Funding dilemmas in a fast-changing world Thomson Prentice Global Health Histories Health and Philanthropy: Leveraging change University of Indiana, August 2006 An embarrassment
More informationDraft Sri Lanka National Health Promotion Policy
Draft Sri Lanka National Health Promotion Policy Table of contents Executive summary...1 Forewords...2 Preamble...3 The Concept for Health Promotion development...4 Guiding Principles...4 Current Sri Lanka
More informationThe Burgeoning Public Health Crisis: Demand Analysis and Market Opportunity for Advanced Trauma Systems in the Developing World
The Burgeoning Public Health Crisis: Demand Analysis and Market Opportunity for Advanced Trauma Systems in the Developing World Globally, the causes of mortality will experience significant shifts over
More informationThe Australian Healthcare System
The Australian Healthcare System Professor Richard Osborne, BSc, PhD Chair of Public Health Deakin University Research that informs this presentation Chronic disease self-management Evaluation methods
More informationLI, Huafang MD., Ph.D. Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine, Shanghai, China
Late Clinical Trials in China LI, Huafang MD., Ph.D. Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine, Shanghai, China Biography Huafang LI, M.D., Ph.D., Chief-Psychiatrist,
More informationClinical Research Associate (CRA) - A Growing Career Path in Biotechnology / Pharmaceutical Industry
Clinical Research Associate (CRA) - A Growing Career Path in Biotechnology / Pharmaceutical Industry By http://www.clinicalresearchassociate cra.com/studyguide/ A clinical research associate (CRA) is a
More informationMortality statistics and road traffic accidents in the UK
Mortality statistics and road traffic accidents in the UK An RAC Foundation Briefing Note for the UN Decade of Action for Road Safety In 2009 2,605 people died in road traffic accidents in the UK. While
More informationDementia: a major health problem for Australia
Dementia: a major health problem for Australia Position Paper 1 September 2001 Professor Anthony Jorm Director, Centre for Mental Health Research, Australian National University Dementia is one of the
More informationUpstate New York adults with diagnosed type 1 and type 2 diabetes and estimated treatment costs
T H E F A C T S A B O U T Upstate New York adults with diagnosed type 1 and type 2 diabetes and estimated treatment costs Upstate New York Adults with diagnosed diabetes: 2003: 295,399 2008: 377,280 diagnosed
More informationThe below tables outline the types of health care services as well as delivery settings:
Assuring Quality Health Care Delivery in Asia Introduction Guk-Hee Suh, PhD, MD, 2014-2016 Chair, ISPOR Asia Consortium Health Service Providers (Clinicians) Committee, and Professor of Psychiatry, Hallym
More informationPatient Access to Cancer Drugs in Nine Countries in the Middle East
Patient Access to Cancer Drugs in Nine Countries in the Middle East Frida Kasteng¹ Nils Wilking² Bengt Jönsson³ ¹i3 Innovus, Stockholm, Sweden ² Karolinska Institutet, Stockholm, Sweden ³ Stockholm School
More informationThe National Survey of Children s Health 2011-2012 The Child
The National Survey of Children s 11-12 The Child The National Survey of Children s measures children s health status, their health care, and their activities in and outside of school. Taken together,
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationNURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH
NURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH May 2008 This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or
More informationWhite Paper CLINICAL RESEARCH IN BELGIUM AN INTRODUCTION
White Paper CLINICAL RESEARCH IN BELGIUM AN INTRODUCTION Table of Contents 1. Introduction... 3 2. Clinical Research Activity in Belgium... 3 3. The Regulatory Landscape in Belgium... 3 4. The Healthcare
More informationUF Health Jacksonville CHNA Implementation Strategy
UF Health Jacksonville CHA Implementation Strategy Adopted by the UF Health Jacksonville Governing Board on: December 7, 2015 This document describes how UF Health Jacksonville (the hospital) plans to
More informationHealthy ageing and disease prevention: The case in South Africa and The Netherlands
Healthy ageing and disease prevention: The case in South Africa and The Netherlands Sebastiana Kalula, 1 Ger Tielen 2 and Monica Ferreira 1 Medical advances, improved health care and prudent health behaviour
More informationHealth and Longevity. Global Trends. Which factors account for most of the health improvements in the 20th century?
8 Health and Longevity The health of a country s population is often monitored using two statistical indicators: life expectancy at birth and the under-5 mortality rate. These indicators are also often
More informationHOSPITAL SUBSECTOR ANALYSIS
HOSPITAL SUBSECTOR ANALYSIS Fourth Health Sector Development Project (RRP MON 41243) A. Introduction 1. The health status of the people of Mongolia has generally improved over the years, and significant
More informationHealth Policy, Administration and Expenditure
Submission to the Parliament of Australia Senate Community Affairs Committee Enquiry into Health Policy, Administration and Expenditure September 2014 Introduction The Australian Women s Health Network
More informationJoint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
More informationTurkey: Your Partner in Healthcare
Turkey: Your Partner in Healthcare Beril Ongen Acıbadem Healthcare Group April 16, 2009 Chicago on behalf of Meri Bahar, Chairwoman of TAIK Health Committee Why receive care abroad? ACCESS BY PATIENTS:
More informationSnapshot Report on Russia s Healthcare Infrastructure Industry
Snapshot Report on Russia s Healthcare Infrastructure Industry According to UK Trade & Investment report, Russia will spend US$ 15bn in next 2 years to modernize its healthcare system. (Source: UK Trade
More informationEvidence-Based Practice for Public Health Identified Knowledge Domains of Public Health
1 Biostatistics Statistical Methods & Theory Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health General Public Health Epidemiology Risk Assessment Population-Based
More informationOccupational Outlook Handbook, 2004-05 Edition
Occupational Outlook Handbook, 2004-05 Edition U.S. Department of Labor Bureau of Labor Statistics Bulletin 2540 Registered Nurses + Chris is pleased with the favorable job outlook. Job security is important
More informationMedical Technologies Market in Turkey
U.S. Commercial Service Medical Technologies Market in Turkey Brief Market Report Prepared by Ebru Olcay, Medical Sector Specialist Turkey: Medical Technologies and Healthcare Market and What Is The Size
More informationThreats and Opportunities the Scientific Challenges of the 21 st Century
Examples from Health Threats and Opportunities the Scientific Challenges of the 21 st Century Professor Dame Sally C Davies, Chief Medical Officer and Chief Scientific Adviser 6 th th February 2013 Annual
More informationWHO & ehealth in Europe The role of ehealth in achieving Universal Health Coverage and strengthening national health systems
WHO & ehealth in Europe The role of ehealth in achieving Universal Health Coverage and strengthening national health systems Clayton Hamilton, ehealth and Innovation WHO Regional Office for Europe Tenth
More informationA Glimpse of Pricing and Reimbursement in the UAE
ISPOR Arabic Network Forum United Arab Emirates Ministry of Health PROS & CONS OF PRICING AND REIMBURSEMENT SYSTEMS IN SAUDI ARABIA, EGYPT, UNITED ARAB EMIRATES, QATAR AND JORDAN A Glimpse of Pricing and
More informationInviting Possibilities. Healthcare. Cover Page- Healthcare Sector Report.indd 1
Inviting Possibilities Healthcare Cover Page- Healthcare Sector Report.indd 1 7/30/13 1:4 PM TABLE OF CONTENTS Overview of Dubai's Healthcare Industry Investment opportunities Medical research and development
More informationTelehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs
Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Telehealth Solutions Enhance Health Outcomes and
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationWasteful spending in the U.S. health care. Strategies for Changing Members Behavior to Reduce Unnecessary Health Care Costs
Strategies for Changing Members Behavior to Reduce Unnecessary Health Care Costs by Christopher J. Mathews Wasteful spending in the U.S. health care system costs an estimated $750 billion to $1.2 trillion
More information2.2 How much does Australia spend on health care?
2.2 How much does Australia spend on health care? Health expenditure occurs where money is spent on health goods and services. Health expenditure data includes health expenditure by governments as well
More informationSUMMARY- REPORT on CAUSES of DEATH: 2001-03 in INDIA
SUMMARY- REPORT on CAUSES of DEATH: 2001-03 in INDIA Background: Long-term mortality measurement by cause, gender and geographic area has been the requirement of every country. With this in view, Medical
More informationHealth at a Glance: Europe 2014
Health at a Glance: Europe 2014 (joint publication of the OECD and the European Commission) Released on December 3, 2014 http://www.oecd.org/health/health-at-a-glance-europe-23056088.htm Table of Contents
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationJapan. Type of Market: Large/Challenging. Overall Rank. 2015 ITA Health IT Top Markets Report 35
Japan Type of Market: Large/Challenging Japan ranked as the top country in this Health IT Top Markets Report, with a favorable demographic profile for Health IT, a largely urbanized population, and sizable
More informationDIVERSIFIED LEADER IN HEALTHCARE STAFFING & OUTSOURCING
DIVERSIFIED LEADER IN HEALTHCARE STAFFING & OUTSOURCING NURSE & ALLIED STAFFING PHYSICIAN STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH February 2009 This presentation contains forward-looking
More informationADMISSION TO THE PSYCHIATRIC EMERGENCY SERVICES OF PATIENTS WITH ALCOHOL-RELATED MENTAL DISORDER
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 ADMISSION TO THE PSYCHIATRIC EMERGENCY SERVICES OF PATIENTS WITH ALCOHOL-RELATED MENTAL DISORDER P.
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More informationIntroduction INTRODUCTION: BURDEN OF CHRONIC DISEASES. The prevalence of chronic noncommunicable
Capacity Building of Advanced Practice Nurse Through Residency Training Program in Thailand : A Challenges to Improve Prevention and Management of Chronic Conditions Introduction INTRODUCTION: BURDEN OF
More informationParallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets
Parallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets Steve Kretschmer, Ipsos, Turkey and Beyza Ozel, Novartis, Turkey 5 Pillars to Success: A Framework
More informationProposal for a Graduate Certificate. Adult Nurse Practitioner. Submitted by the School of Nursing West Lafayette Campus
Graduate Council Document 06-4b Approved by the Graduate Council 4/27/06 Proposal for a Graduate Certificate Adult Nurse Practitioner Submitted by the School of Nursing West Lafayette Campus Purdue University
More informationRegistered Nurse (RN) and Nursing Careers, Jobs, and Employment Information
www.careersinghana.com Email : info@careersinghana.com Tel: +233 245649846 Registered Nurse (RN) and Nursing Careers, Jobs, and Employment Information Registered Nurse and Nursing Career Overview Registered
More informationThe Physician Workforce. 2012 Physician Survey Report. Dianne Reynolds-Cane, MD, Director. Virginia Department of Health Professions
The Physician Workforce 2012 Physician Survey Report Dianne Reynolds-Cane, MD, Director Virginia Department of Health Professions Joint Commission on Health Care September 17, 2013 Updated 9/18/13 Healthcare
More informationThe Burden of Cancer in Asia
P F I Z E R F A C T S The Burden of Cancer in Asia Medical Division PG283663 2008 Pfizer Inc. All rights reserved. Printed in USA/December 2008 In 2002, 4.2 million new cancer cases 39% of new cases worldwide
More informationKey Priority Area 1: Key Direction for Change
Key Priority Areas Key Priority Area 1: Improving access and reducing inequity Key Direction for Change Primary health care is delivered through an integrated service system which provides more uniform
More informationIntroduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
More informationAnnual Statistics. MANITOBA HEALTH Health Information Management
Annual Statistics 2012 2013 MANITOBA HEALTH Health Information Management This page intentionally left blank. Manitoba Health Annual Statistics 2012 2013 2 Table of Contents Preface...7 How to Use This
More informationSWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness
SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment
More informationINVITATION LETTER ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC.
INVITATION LETTER COUNTRY: RWANDA SOURCE OF FUNDS: ORDINARY BUDGET ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC. REFERENCE NUMBER: 034/CS/ICS/2014-2015/RBC-MRC
More informationMEDICAL DIRECTOR: ROLE AND RESPONSIBILITIES AS LEADER AND MANAGER
MEDICAL DIRECTOR: ROLE AND RESPONSIBILITIES AS LEADER AND MANAGER FUNCTIONS AND ASSOCIATED TASKS Function 1 - Administrative The medical director participates in administrative decision making and recommends
More informationUniversity of Maryland College Park School of Public Health
In Focus: A Summary of the Asian American Community Group Reports Korean Community Needs Assessment Summary Report Research Team Maryland Asian American Health Solutions (MAAHS) University of Maryland
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationPROPOSAL GRADUATE CERTIFICATE ADVANCED PRACTICE ONCOLOGY SCHOOL OF NURSING TO BE OFFERED AT PURDUE UNIVERSITY WEST LAFAYETTE CAMPUS
Graduate Council Document 08-20b Approved by the Graduate Council November 20, 2008 PROPOSAL GRADUATE CERTIFICATE ADVANCED PRACTICE ONCOLOGY SCHOOL OF NURSING TO BE OFFERED AT PURDUE UNIVERSITY WEST LAFAYETTE
More informationAdvancing research: a physician s guide to clinical trials
Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer
More informationSelected Health Status Indicators DALLAS COUNTY. Jointly produced to assist those seeking to improve health care in rural Alabama
Selected Health Status Indicators DALLAS COUNTY Jointly produced to assist those seeking to improve health care in rural Alabama By The Office of Primary Care and Rural Health, Alabama Department of Public
More informationPrinciples on Health Care Reform
American Heart Association Principles on Health Care Reform The American Heart Association has a longstanding commitment to approaching health care reform from the patient s perspective. This focus including
More informationHealth and Health Care for an Aging Population
Health and Health Care for an Aging Population May 2013 Policy Summary of The Canadian Medical Association December 2013 December 2013 Page 1 1) Introduction and Context: In 2010, 14% of Canada s population
More informationGlobal Fund TB Grants in Asia and the Pacific. Swarup Sarkar Director, Asia Pacific CCM Unit ICAPP, 2009, Bali
Global Fund TB Grants in Asia and the Pacific Swarup Sarkar Director, Asia Pacific CCM Unit ICAPP, 2009, Bali Outline GF Financing on TB Progress: case detection rate, cure rate March towards MDG : Incidence
More informationCorrectional Health Care Cost Saving Strategies. July 24, 2014
Correctional Health Care Cost Saving Strategies July 24, 2014 Agenda Facility health care issues Medicaid reimbursements Claims administration strategies Preferred provider partnerships Prescription medicine
More informationNICHD Extramural Associates Program Partnerships for Emerging Research Institutions The National Academies September 13, 2007
NICHD Extramural Associates Program Partnerships for Emerging Research Institutions The National Academies September 13, 2007 Regina Smith James, M.D. Director, Extramural Associates Program NICHD, NIH,
More informationSYLLABUS. Path-217. Haneline MT, Meeker WC. Introduction to Public Health for Chiropractors. Sudbury, MA: Jones and Bartlett Publishers, 2011.
SYLLABUS NAME OF COURSE: PUBLIC HEALTH 1 - PATH 221 LENGTH OF COURSE: COURSE DESCRIPTION: PREREQUISITES: COURSE OFFERED BY: REQUIRED TEXTBOOK: 4 units, (4 hours lecture/wk.) Aspects of community health,
More informationDisability Allowance Application
Disability Allowance Application CLIENT NUMBER If you need help with this form call us on % 0800 559 009. Who can get Disability Allowance? Please read this before you start Name If you, or a family member,
More informationNurse Practitioner Frequently Asked Questions
HEALTH SERVICES Nurse Practitioner Frequently Asked Questions The Frequently Asked Questions (FAQs) have been designed to increase awareness and understanding of the Nurse Practitioner role within the
More informationInfoset builds software and services to advantage business operations and improve patient s life
Infoset builds software and services to advantage business operations and improve patient s life Clinical Data Management ecrf & EDC Patient Support Programs Medication Adherence Mobile e-health Big Data
More informationExpanding Health Coverage in Kentucky: Why It Matters. September 2009
Expanding Health Coverage in Kentucky: Why It Matters September 2009 As the details of federal health reform proposals consume the public debate, reflecting strong and diverse opinions about various options,
More informationClinical Research in Mauritius
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
More informationTHE CZECH MARKET WITH IN VITRO DIAGNOSTIC MEDICAL DEVICES
THE CZECH MARKET WITH IN VITRO DIAGNOSTIC MEDICAL DEVICES 1 Motto: Finances used in relation to IVD are not costs but true investments in health. Czech Association of In Vitro Diagnostic Medical Suppliers
More informationPUBLIC HEALTH SEATTLE & KING COUNTY
PUBLIC HEALTH SEATTLE & KING COUNTY ABOUT THE DIVISION The mission of the Prevention Division of Public Health Seattle & King County is to provide King County s disease surveillance and investigation,
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationNATIONAL HEALTH ACCOUNTS:
THE REPUBLIC OF UGANDA MINISTRY OF HEALTH NATIONAL HEALTH ACCOUNTS: KEY MESSAGES (FY2010/11 & 2011/12) NATIIONAL HEALTH ACCOUNTS: KEY MESSAGES Introduction The overall purpose of the National Health Accounts
More informationOFFICIALLY ON PAPER SUPREME COUNCIL OF HEALTH REPORT 2014
OFFICIALLY ON PAPER EVERY YEAR SUPREME COUNCIL OF HEALTH ISSUES AN ANNUAL REPORT PROVIDING AN UPDATE ON THE REFORMS BEING UNDERTAKEN BY THE COUNCIL AND ALL PARTNERS. Qatar s Supreme Council of Health was
More informationMarieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014
Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration
More informationWelcome to Angkor Hospital for Children, Siem Reap, Cambodia. SOM SOPHAL Director of Nursing Angkor Hospital for Children
Welcome to Angkor Hospital for Children, Siem Reap, Cambodia SOM SOPHAL Director of Nursing Angkor Hospital for Children Contents: 1. Cambodian mapping 2. Background/recent history 3. Health care system
More informationECONOMIC COSTS OF PHYSICAL INACTIVITY
ECONOMIC COSTS OF PHYSICAL INACTIVITY This fact sheet highlights the prevalence and health-consequences of physical inactivity and summarises some of the key facts and figures on the economic costs of
More informationBURDEN OF LIVER DISEASE IN BRAZIL
BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000
More information